A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
149actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-06 | actual | When the study began enrolling |
| Primary completion | 2025-05-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-16 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertrophic Cardiomyopathy
Intervention
- Other: Quality of life assessment
Primary outcomes
what the primary-completion date above is the date OFParticipant age
measured Baseline
Participant sex
measured Baseline
Participant height
measured Baseline
Participant weight
measured Baseline
Participant smoking status
measured Baseline
Participant drinking status
measured Baseline
Participant employment status
measured Baseline
Family members co-residing with participant
measured Baseline
Participant comorbidities
measured Baseline
Participant mental disorders under current medical treatment
measured Baseline
Time from first diagnosis of mental disorders
measured Baseline
Family history of hypertrophic cardiomyopathy (HCM) in participants with diagnosed HCM
measured Baseline
Period from first diagnosis of hypertrophic cardiomyopathy (HCM) in participants with diagnosed HCM
measured Baseline
New York Heart Association functional classification (self-reported) in participants with diagnosed hypertrophic cardiomyopathy
measured Baseline
History of non-drug therapy in participants with diagnosed hypertrophic cardiomyopathy
measured Baseline
Participant need for support/caregivers in participants with diagnosed hypertrophic cardiomyopathy
measured Baseline
Participant current medications for hypertrophic cardiomyopathy in participants with diagnosed with HCM
measured Baseline
Patient-reported health-related quality of life assessed by using the European Quality of Life 5 Dimension 5 Level (EQ-5D-5L) questionnaire
measured Baseline
Patient-reported health-related quality of life assessed by using the Hospital Anxiety Depression Scale (HADS)
measured Baseline
Patient-reported health-related quality of life assessed by using the Kansas City Cardiomyopathy Questionnaire (KCCQ)
measured Baseline
Publications
- PMID 40641461 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed